Open access
Open access
Powered by Google Translator Translator

HIV

Late diagnosis of HIV: an updated consensus definition

14 Feb, 2023 | 10:49h | UTC

Late diagnosis of HIV: An updated consensus definition – HIV Medicine

 

RCT | Pregnancy and neonatal safety of PrEP for HIV prevention initiated during pregnancy vs. afterwards

9 Feb, 2023 | 13:55h | UTC

Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial – The Lancet HIV (link to abstract – $ for full-text)

 

Update guidelines for women with HIV who are virally suppressed incorporate breastfeeding their infants as a viable option

6 Feb, 2023 | 13:40h | UTC

Update to Clinical Guidelines for Infant Feeding Supports Shared Decision Making: Clarifying Breastfeeding Guidance for People with HIV – HIV.gov

 

Commentary on Twitter

 

M-A | Revisiting the evidence base for modern-day practice of the treatment of toxoplasmic encephalitis

27 Jan, 2023 | 12:14h | UTC

Revisiting the Evidence Base for Modern-Day Practice of the Treatment of Toxoplasmic Encephalitis: A Systematic Review and Meta-Analysis – Clinical Infectious Diseases

 

Phase 2 RCT | Lenacapavir every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV

27 Jan, 2023 | 12:00h | UTC

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial – The Lancet HIV (link to abstract – $ for full-text)

 

BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022.

15 Dec, 2022 | 13:52h | UTC

BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022 – HIV Medicine

Related: Consensus Recommendations | Antiretroviral drugs for treatment and prevention of HIV infection in adults.

 

Consensus Recommendations | Antiretroviral drugs for treatment and prevention of HIV infection in adults.

2 Dec, 2022 | 14:45h | UTC

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults2022 Recommendations of the International Antiviral Society–USA Panel – JAMA (free for a limited period)

Invited Commentary: Ending the HIV Epidemic: We Have the Tools, Do We Have the Will? – JAMA (free for a limited period)

Author Interview: Advances in Treatment and Prevention of HIV – JAMA

 

How applicable is the single-dose AMBITION regimen for HIV-associated cryptococcal meningitis to high-income settings?

29 Sep, 2022 | 13:26h | UTC

How applicable is the single-dose AMBITION regimen for HIV-associated cryptococcal meningitis to high-income settings? – Clinical Infectious Diseases

 

Commentary on Twitter

Under a https://creativecommons.org/licenses/by/4.0/ license

 

Global, regional, and national burdens of HIV and other sexually transmitted infections in adolescents and young adults aged 10–24 years from 1990 to 2019: a trend analysis based on the Global Burden of Disease Study 2019.

16 Sep, 2022 | 12:50h | UTC

Global, regional, and national burdens of HIV and other sexually transmitted infections in adolescents and young adults aged 10–24 years from 1990 to 2019: a trend analysis based on the Global Burden of Disease Study 2019 – The Lancet Child & Adolescent Health (link to abstract – $ for full-text)

 

Commentary on Twitter

 

Systematic Review | Association of HIV infection with cardiovascular pathology based on advanced cardiovascular imaging.

15 Sep, 2022 | 13:02h | UTC

Association of HIV Infection With Cardiovascular Pathology Based on Advanced Cardiovascular Imaging: A Systematic Review – JAMA (free for a limited period)

Editorial: HIV, Subclinical Cardiovascular Disease, and Clinical Progression: Insights From Immunologic Heterogeneity – JAMA (free for a limited period)

 

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomized ODYSSEY trial.

8 Sep, 2022 | 14:33h | UTC

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial – The Lancet HIV

 

Commentary on Twitter

 

Cohort Study | Dolutegravir in pregnancy as compared with current HIV regimens.

1 Sep, 2022 | 11:55h | UTC

Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States – New England Journal of Medicine (link to abstract – $ for full-text)

Related:

RCT | 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy.

WHO Recommends Dolutegravir as Preferred HIV Treatment Option in All Populations

Week 96 results from a RCT: Efficacy and safety of dolutegravir or darunavir combined with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection.

RCT: Efficacy and safety of switching to the 2-drug regimen Dolutegravir/Lamivudine vs. continuing a 3- or 4-Drug regimen for maintaining virologic suppression in adults living with HIV-1.

RCT: Low-cost, easy to take antiretroviral treatment based on Dolutegravir as first- or second-Line therapy found to be non-inferior to standard care for treating HIV-1 infection in children.

RCT: Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV.

Randomized controlled trial compared three antiretroviral regimens started in pregnant women with HIV

Randomized Trial: Switching to Dolutegravir/Lamivudine Two-Drug Regimen Noninferior to Continuing a Tenofovir Alafenamide–Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1

 

Commentary on Twitter

 

M-A | Incidence and mortality of non-AIDS-defining cancers among people living with HIV.

23 Aug, 2022 | 13:26h | UTC

Incidence and mortality of non-AIDS-defining cancers among people living with HIV: A systematic review and meta-analysis – eClinicalMedicine

Related: Study: Cancer Patients with HIV Infection Have Worse Outcomes

 

Consensus Statement | Preoperative management of medications for rheumatologic and HIV diseases.

22 Aug, 2022 | 12:22h | UTC

Preoperative Management of Medications for Rheumatologic and HIV Diseases: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Related:

Preoperative Evaluation and Management of Patients With Select Chronic Gastrointestinal, Liver, and Renal Diseases – Mayo Clinic Proceedings

Preoperative Management of Medications for Neurologic Diseases – Mayo Clinic Proceedings

Preoperative Management of Medications for Psychiatric Diseases: Society for Perioperative Assessment and Quality Improvement Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Gastrointestinal and Pulmonary Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Endocrine, Hormonal, and Urologic Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Opioid and Nonopioid Analgesics: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Surgical Patients Using Dietary Supplements – Mayo Clinic Proceedings

Perioperative Evaluation and Management of Endocrine Disorders – Mayo Clinic Proceedings

Preoperative Cardiac Risk Assessment – Mayo Clinic Proceedings

Preoperative Evaluation Before Noncardiac Surgery – Mayo Clinic Proceedings

Perioperative Cardiac Risk Reduction in Noncardiac Surgery – Mayo Clinic Proceedings

Examining Risk: A Systematic Review of Perioperative Cardiac Risk Prediction Indices – Mayo Clinic Proceedings

Perioperative Venous Thromboembolism Prophylaxis – Mayo Clinic Proceedings

 

CDC interim guidance for prevention and treatment of Monkeypox in persons with HIV infection.

17 Aug, 2022 | 14:36h | UTC

Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection — United States, August 2022 – Morbidity and Mortality Weekly Report

 

Systematic Review | Accuracy of measures for antiretroviral adherence in people living with HIV.

17 Aug, 2022 | 14:11h | UTC

Accuracy of measures for antiretroviral adherence in people living with HIV – Cochrane Library

Summary: Are there good ways to find out if people living with HIV are taking their medicines every day? – Cochrane Library

 

M-A | Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV.

9 Aug, 2022 | 12:41h | UTC

Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis – eClinicalMedicine

 

RCT | 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy.

4 Aug, 2022 | 14:33h | UTC

72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study – The Lancet HIV

Related:

WHO Recommends Dolutegravir as Preferred HIV Treatment Option in All Populations

Week 96 results from a RCT: Efficacy and safety of dolutegravir or darunavir combined with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection.

RCT: Efficacy and safety of switching to the 2-drug regimen Dolutegravir/Lamivudine vs. continuing a 3- or 4-Drug regimen for maintaining virologic suppression in adults living with HIV-1.

RCT: Low-cost, easy to take antiretroviral treatment based on Dolutegravir as first- or second-Line therapy found to be non-inferior to standard care for treating HIV-1 infection in children.

RCT: Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV.

Randomized controlled trial compared three antiretroviral regimens started in pregnant women with HIV

Randomized Trial: Switching to Dolutegravir/Lamivudine Two-Drug Regimen Noninferior to Continuing a Tenofovir Alafenamide–Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1

 

Network M-A | Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy.

4 Aug, 2022 | 13:30h | UTC

Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy – a systematic literature review and network meta-analysis – eClinicalMedicine

 

Commentary on Twitter

 

WHO Guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations.

2 Aug, 2022 | 12:41h | UTC

Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations – World Health Organization

News Release: WHO publishes new guidelines on HIV, hepatitis and STIs for key populations – World Health Organization

 

M-A | Worldwide occurrence of HIV-associated neurocognitive disorders and its associated factors.

22 Jul, 2022 | 11:30h | UTC

Worldwide Occurrence of HIV-Associated Neurocognitive Disorders and Its Associated Factors: A Systematic Review and Meta-Analysis – Frontiers in Psychiatry

 

WHO Guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia.

5 Jul, 2022 | 12:22h | UTC

WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia – World Health Organization

News Release: Visceral leishmaniasis and HIV coinfection: WHO publishes new guideline with region-specific treatment recommendations – World Health Organization

WHO Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV.

5 Jul, 2022 | 12:23h | UTC

Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV – World Health Organization

RCT: In people with HIV, treating precancerous anal lesions cuts risk of anal cancer by more than half.

21 Jun, 2022 | 11:11h | UTC

News Release: In people with HIV, treating precancerous anal lesions cuts risk of anal cancer by more than half – National Institutes of Health

Original Study: Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 

M-A: Benefits and risks of rapid initiation of antiretroviral therapy in patients with HIV.

21 Jun, 2022 | 10:41h | UTC

Benefits and Risks of Rapid Initiation of Antiretroviral Therapy: A Systematic Review and Meta-Analysis – Frontiers in Pharmacology

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.